Remimazolam did not improve overall recovery scores after meniscectomy
A randomized trial in adults undergoing elective arthroscopic meniscectomy found no significant difference in quality of recovery on postoperative day 1 between remimazolam-based and propofol-based total intravenous anesthesia. The global QoR-40 score was 166.1 ± 16.8 in the propofol group and 170.6 ± 13.6 in the remimazolam group, a separation that did not reach statistical significance. For a procedure built around early mobilization and same-day or next-day functional recovery, the result is clinically useful: anesthetic selection changed some perioperative physiology, but it did not move the main patient-reported endpoint.
The trial enrolled 80 adults, and 71 completed the QoR-40 assessment and entered the final analysis. Thirty-six patients were analyzed in the propofol arm and 35 in the remimazolam arm. Because the primary outcome was a patient-centered composite that captures physical comfort, physical independence, emotional state, psychological support, and pain, the null result carries more weight than a simple recovery-room metric. It suggests that for uncomplicated arthroscopic meniscectomy, the average patient experiences a broadly similar overall recovery trajectory whether the anesthetic backbone is propofol or remimazolam.
Hemodynamic stability came at the expense of slower emergence
A single intraoperative difference stood out sharply: hypotension requiring ephedrine was more frequent with propofol, occurring in 44.4% of patients compared with 17.1% in the remimazolam group. In anesthesia practice, that pattern is biologically plausible. Propofol is well known for vasodilatory and myocardial depressant effects, while remimazolam, an ultrashort-acting benzodiazepine, tends to preserve circulation more gently during induction and maintenance. For patients who cannot tolerate swings in blood pressure, especially older adults or those with limited cardiovascular reserve, the hemodynamic profile may matter as much as the recovery questionnaire.
The tradeoff was slower awakening. Time to full alertness was 18 [15–24] minutes with propofol and 37 [31–45] minutes with remimazolam, and the post-anesthesia care unit stay was also longer in the remimazolam group at 38 [30–50] minutes versus 30 [30–39] minutes. Those differences are not trivial in a setting designed for fast turnover and quick discharge. A drug that keeps blood pressure steadier can still stretch the recovery timeline if consciousness returns more gradually.
Emotional recovery favored remimazolam in exploratory analysis
One exploratory signal separated the two groups: the emotional-state domain of the QoR-40 was higher with remimazolam, 39.2 ± 2.5 versus 37.0 ± 4.3 with propofol. This was not the trial’s primary endpoint, and it should not be overread, but it is clinically interesting. Emotional recovery after surgery often reflects more than sedation depth alone. Anxiety on emergence, perceived calmness in the immediate postoperative period, and the quality of the waking experience may all influence how patients rate the psychological side of recovery.
The finding fits the pharmacology only partially. Remimazolam’s benzodiazepine mechanism may produce a smoother subjective transition from anesthesia to wakefulness for some patients, yet the same sedative effect likely explains the longer time to full alertness. In other words, the emotional benefit, if real, arrived alongside a slower return to baseline arousal. For clinicians, the signal is suggestive rather than definitive: remimazolam may change how recovery feels without changing the overall QoR-40 score enough to matter at the population level.
The trial population was deliberately narrow
This study focused on adults 19 years or older with American Society of Anesthesiologists Physical Status I to III who were scheduled for elective arthroscopic meniscectomy under general anesthesia. Patients with airway-related disease, uncontrolled asthma or pneumonia, allergy to propofol or benzodiazepines, impaired renal or hepatic function, left ventricular ejection fraction below 55%, pregnancy or breastfeeding, and substance abuse history were excluded. The result is a relatively clean surgical cohort, which improves internal validity but also limits how far the findings can be stretched.
Arthroscopic meniscectomy is a useful model for perioperative recovery research because the surgery is common, the incision burden is small, and discharge usually occurs within a day. Pain, mobility, alertness, nausea, and emotional comfort all matter, but the operation does not impose the physiological stress of major abdominal or thoracic surgery. If a difference between anesthetics exists in this setting, it is likely to be subtle. The absence of a global QoR-40 benefit therefore does not rule out value in higher-risk operations; it only says the advantage was not large enough to register here.
What the physiology suggests for day-to-day anesthesia choices
The contrast between the two anesthetics reflects two different priorities. Propofol offers familiar pharmacology and rapid awakening, but its hemodynamic cost can be real, especially during induction and maintenance. Remimazolam appears to buffer blood pressure more effectively, yet the delayed emergence and longer PACU stay may offset some operational advantage. In a high-throughput orthopedic pathway, an extra 10 to 20 minutes of recovery room time can influence staffing, bed flow, and discharge sequencing.
Patient-reported recovery should remain central in this debate. A medication can look efficient from the anesthesia workstation while still failing to improve the patient’s lived recovery experience. This trial places those two realities side by side: measurable circulatory stability with remimazolam, faster wakefulness with propofol, and no meaningful separation in the composite recovery score that most closely approximates how patients actually feel the next day.
The practical message stays narrow
For elective arthroscopic meniscectomy, remimazolam did not outperform propofol on the main quality-of-recovery endpoint. The most consistent advantage was fewer episodes of hypotension requiring ephedrine, while the clearest downside was slower return to full alertness and a longer PACU stay. One exploratory emotional-domain benefit appeared in the remimazolam arm, but it did not translate into a better global recovery score.
The unanswered questions are narrower than they first appear: whether the emotional-domain signal persists in larger samples, whether higher-risk surgical populations would show a stronger QoR separation, and whether blood pressure stability can justify slower emergence in routine ambulatory pathways. Those are the issues that will determine whether remimazolam becomes a preference-driven alternative or simply another acceptable option in short orthopedic anesthesia.